Two Sigma Investments, LP Checkpoint Therapeutics, Inc. Transaction History

Two Sigma Investments, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.02 - $10.6 $75,748 - $787,187	-74,263 Reduced 61.7%	46,098 $48,000
Q2 2022 Aug 15, 2022	SELL	$0.97 - $1.77 $248,991 - $454,344	-256,692 Reduced 68.08%	120,361 $124,000
Q1 2022 May 16, 2022	BUY	$1.53 - $3.25 $576,891 - $1.23 Million	377,053 New	377,053 $667,000
Q4 2021 Feb 14, 2022	SELL	$2.68 - $4.46 $803,549 - $1.34 Million	-299,832 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.5 - $3.53 $250,925 - $354,306	100,370 Added 50.32%	299,832 $989,000
Q2 2021 Aug 16, 2021	SELL	$2.36 - $3.2 $215,482 - $292,179	-91,306 Reduced 31.4%	199,462 $588,000
Q1 2021 May 17, 2021	BUY	$2.6 - $4.16 $381,568 - $610,509	146,757 Added 101.91%	290,768 $913,000
Q4 2020 Feb 16, 2021	BUY	$2.19 - $2.96 $315,384 - $426,272	144,011 New	144,011 $382,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $351M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.